Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Notification of Major Interest in Shares

27 Jul 2012 12:12

For filings with issuer exclude the annex

TR-1:NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underly Silence Therapeutics plc ing issuer of existing shares to which

voting rights are attached: ii

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which

voting rights are attached An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject t Hedger Management SA o the notification obligation : iii 4. Full name of shareholder(s) (if different from 3.):iv 5. Date of the transaction and date 27 July 2012on which the threshold is crossed or reached: v 6. Date on which issuer notified: 27 July 2012 7. Threshold(s) that is/are crossed Below 8%, Below 3% or reached: vi, vii 8. Notified details: A: Voting rights attached to shares viii, ix

Class/type of Situation previous to Resulting situation after the triggering t shares the triggering transa ransaction

cti on if possible

using the Number of Number of Number Number of voting % of voting rightISIN CODE Shares Voting R of share rights s x ights s Direct xi xii Direct Indirect Direct Indirect

GB0008433350 50,000,000 50,000,000 B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of financia Expiration Exercise/ Number of voting % of voting l instrument date xiii rights that may b rights Conversion e acquired if the Period xiv instrument is exe rcised/ converte d. N/A

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

xv, xvi Resulting situation after the triggering transaction Type of finan Exercise Expiration Exercise/ Number of voting % of voting rigcia l inst price date xvii Conversion rights inst hts xix, rument period rument refers to xviii xx N/A Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to ho ld voting rights: 13. Additional informatio n: 14. Contact name: Charles John Bennett

15. Contact telephone number: +41 22 809 9500

XLON
Date   Source Headline
21st Mar 20127:00 amPRNUnaudited Preliminary Results
19th Mar 20127:00 amPRNNotification of Preliminary Results
10th Feb 20127:00 amPRNSilence Therapeutics Announces Board Changes and New CEO
27th Jan 20124:40 pmRNSSecond Price Monitoring Extn
27th Jan 20124:35 pmRNSPrice Monitoring Extension
26th Jan 20127:00 amPRNTR-1: Notifications of Major Interest in Shares
23rd Jan 20127:00 amPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
9th Jan 20127:00 amPRNSilence signs collaboration with miRagen Therapeutics
6th Jan 20127:00 amPRNResearch and Development Collaboration Update
30th Dec 20117:00 amPRNTotal Voting Rights
20th Dec 20114:40 pmRNSSecond Price Monitoring Extn
20th Dec 20114:35 pmRNSPrice Monitoring Extension
20th Dec 20117:00 amPRNAdditional Listing
12th Dec 20117:00 amPRNPositive Response by USPTO
9th Dec 20114:40 pmRNSSecond Price Monitoring Extn
9th Dec 20114:35 pmRNSPrice Monitoring Extension
7th Dec 20111:27 pmPRNPositive outcome from oral hearing at Patent Office
22nd Nov 20114:40 pmRNSSecond Price Monitoring Extn
22nd Nov 20114:35 pmRNSPrice Monitoring Extension
8th Nov 20117:00 amPRNSilence Therapeutics provides update
24th Oct 20117:00 amPRNCollaboration with Mirna Therapeutics
14th Oct 20117:00 amPRNGrant of options
3rd Oct 20117:00 amPRNDirectors’ share purchases
21st Sep 20117:00 amPRNAppointment of Chief Business Officer
21st Sep 20117:00 amPRNInterim Results for the Six Months Ended 30 June 2011
20th Sep 20117:00 amPRNAppointment of Chief Executive Officer
14th Sep 201110:32 amPRNNotice of Results
13th Sep 20114:40 pmRNSSecond Price Monitoring Extn
13th Sep 20114:35 pmRNSPrice Monitoring Extension
12th Sep 20119:24 amPRNSilence & InteRNA Technologies collaboration
8th Sep 20114:40 pmRNSSecond Price Monitoring Extn
8th Sep 20114:35 pmRNSPrice Monitoring Extension
5th Sep 20114:40 pmRNSSecond Price Monitoring Extn
5th Sep 20114:35 pmRNSPrice Monitoring Extension
1st Sep 20114:40 pmRNSSecond Price Monitoring Extn
1st Sep 20114:35 pmRNSPrice Monitoring Extension
31st Aug 20114:40 pmRNSSecond Price Monitoring Extn
31st Aug 20114:35 pmRNSPrice Monitoring Extension
26th Aug 20114:40 pmRNSSecond Price Monitoring Extn
26th Aug 20114:35 pmRNSPrice Monitoring Extension
23rd Aug 20114:41 pmRNSSecond Price Monitoring Extn
23rd Aug 20114:35 pmRNSPrice Monitoring Extension
22nd Aug 20114:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20114:35 pmRNSPrice Monitoring Extension
18th Aug 20114:41 pmRNSSecond Price Monitoring Extn
18th Aug 20114:35 pmRNSPrice Monitoring Extension
12th Aug 20114:40 pmRNSSecond Price Monitoring Extn
12th Aug 20114:35 pmRNSPrice Monitoring Extension
11th Aug 20114:40 pmRNSSecond Price Monitoring Extn
11th Aug 20114:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.